CD274 and neoplasm: Preclinical studies show that combination therapy with anti‐Ly6G antibodies and PD‐L1 inhibitor enhances cytotoxic T cells infiltration, significantly reducing tumour burden and improving the efficacy of ICB,123, 124 although no Ly6G‐targeting drug has entered clinical trials to date.